GLP-1 Side Effects: The Ones That Mean "Keep Going" vs the Ones That Mean "Call Someone Now"

Almost everyone starting a GLP-1 gets side effects, and almost all of them are the same handful of gut symptoms that show up worst right after a dose goes up and fade as the body adjusts. Because they're so common, two opposite mistakes happen constantly: people quit over effects that would have settled in two weeks, and people wait out effects that actually warranted a call. The whole skill is telling those two categories apart.

This is not a substitute for your prescriber. It's a map of which bucket a symptom probably belongs in, so you know when to ride it out and when to pick up the phone.

The expected bucket: uncomfortable, common, usually temporary

These are the GI effects nearly everyone knows about, and they cluster right after each dose increase because that's when your gut is adjusting to more drug:

• Nausea — the signature effect, worst early and after step-ups
• Vomiting and diarrhea
• Constipation
• Reduced appetite and early fullness — technically how the drug works, but jarring at first
• Fatigue, burping, indigestion

These are the reason the drugs are titrated so slowly. The low starting doses aren't the effective weight-loss doses — they exist to let your gut catch up and to keep this bucket manageable. Most of it eases over days to a couple of weeks at each dose. The people who quit in week one often quit at the exact moment they were closest to the symptoms settling.

Managing this bucket is mostly boring and effective: smaller meals, less fat and less fried food, hydration, and not jumping the titration schedule. If nausea is genuinely unmanageable at a new dose, the fix is often to slow the titration — stay at the current dose longer — rather than abandon the drug. That's a prescriber conversation, not a quit decision.

I keep a fuller, plain-language rundown of the common effects and what actually helps here.

The "call someone" bucket: less common, don't wait it out

A smaller set of symptoms are not part of the normal adjustment and warrant contacting a clinician promptly — some urgently:

• Severe, persistent abdominal pain, especially pain that bores through to your back and comes with vomiting. This is the classic presentation of pancreatitis, a known (uncommon) risk, and it is not something to ride out.
• Gallbladder symptoms — pain in the upper right abdomen, especially after meals, sometimes with fever, nausea, or yellowing of the skin/eyes. Rapid weight loss of any kind raises gallbladder risk, and these drugs cause rapid weight loss.
• Signs of dehydration from prolonged vomiting or diarrhea — dizziness, very dark urine, not urinating. Dehydration is also the main pathway to a rarer kidney complication, which is why persistent GI loss isn't just uncomfortable, it's the thing that can cascade.
• Severe allergic reaction — swelling of the face/lips/throat, trouble breathing. Emergency, not a phone call.

The rule of thumb: the expected bucket is discomfort that's improving or holding steady. The call bucket is pain that's severe, symptoms that are worsening rather than settling, or anything involving breathing, a swollen belly you can't explain, or signs your body is drying out. When a symptom crosses from "annoying and stable" to "severe or escalating," that's your signal — regardless of what bucket you assumed it was in.

One thing you'll read about that the FDA has not concluded

Because honesty matters more than reassurance here: you may see alarming headlines about a rare eye condition (NAION, a form of sudden vision loss) linked to semaglutide. Here's the careful version. Some observational research raised a possible signal, and European regulators added it as a very rare possible side effect to the product information. As of this writing, the U.S. FDA has not added NAION to the label as an established risk, and a possible association in observational data is not the same as a proven cause.

What to do with that: don't panic, and don't dismiss it. If you experience sudden vision changes or sudden vision loss on a GLP-1, treat that as a "call someone now" symptom and get evaluated — that advice holds regardless of how the regulatory question eventually resolves. The point is to give you the actual state of the evidence, not a scarier or calmer version than the data supports.

Reporting is part of the system — and it's free

If you have a side effect that seems serious or unexpected, reporting it to the FDA's MedWatch program is genuinely useful — it's how rare signals (including the eye question above) get detected in the first place. It takes a few minutes and doesn't replace calling your own clinician; it adds your data to the system that catches the things individual doctors can't see alone. The how-to is here.

The one-line version

Most GLP-1 side effects are common GI effects that peak after dose increases and settle within days to weeks — ride those out, manage them, and slow the titration rather than quitting. A shorter list — severe abdominal pain, gallbladder symptoms, dehydration, allergic reactions, sudden vision changes — is not part of normal adjustment and warrants prompt contact. The skill isn't tolerating more; it's knowing which bucket you're in, and picking up the phone the moment a symptom crosses from stable-and-annoying to severe-or-escalating.

Side-effect information reflects current FDA-approved prescribing information for the brand products as of July 2026. The NAION question reflects the regulatory state as of this writing. This is general information, not medical advice — for any concerning symptom, contact your clinician or emergency services.